Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Key Insights Insiders appear to have a vested interest in PYC Therapeutics' growth, as seen by their sizeable ownership...
PYC Therapeutics today announces the results of a study conducted in human 3-dimensional models derived from patients with end-stage renal failure due to Autosomal Dominant Polycystic Kidney Disease (PKD). The results demonstrate that an investigational drug candidate designed by PYC (known as PYC-003) to address this disease at its root cause is effective. These 3D patient-derived cyst models represent the 'gold-standard' pre-clinical assay for evaluating drug candidates in this indication[8].